Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1

NCT06300307 is registered in ClinicalTrials.gov with ARTHEx Biotech S.L. as lead sponsor.

NCT NCT06300307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06300307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1
Lead sponsor
ARTHEx Biotech S.L.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 15, 2024
Completion date
July 31, 2027
Enrollment
56 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myotonic dystrophy 1